China government to probe 60 firms over drug prices

July 4, 2013

China's top economic planner is to investigate 60 pharmaceutical companies for excessive charges, including several joint ventures with foreign firms, state media reported Thursday.

The National Development and Reform Commission (NDRC), which is already investigating foreign baby formula producers over , will send teams to check wholesale prices and production costs of dozens of companies, the Securities Daily said.

In a statement the NDRC said firms targeted in the investigation include Sino-foreign joint ventures with Britain's GlaxoSmithKline, Germany's Boehringer-Ingelheim and global healthcare firm MSD.

The inquiry will also look at several Chinese companies, among them industry leader Sinopharm Group and Jiangsu Hengrui Medicine, which specialises in anti-tumour drugs.

Chinese police are already investigating senior staff of GlaxoSmithKline in China for suspected "economic crimes" but it was unclear whether there was any connection between the two probes.

The NDRC, which helps regulate prices in China, said the four-month survey aimed to "timely set and adjust drug prices".

Analysts said providing healthcare at affordable prices was a political platform of China's ruling Communist Party.

"There always has been a lot of pressure to make sure that common drugs are available at very cheap prices relative to what they would be sold for in a lot of Western markets," said Ben Cavender of the China Market Research Group consultancy.

It is also common practice for Chinese pharmaceutical firms to offer doctors and hospitals bribes to have their products used, industry officials say.

State media reported Tuesday that the NDRC had launched a probe of foreign baby formula makers for high prices resulting from a monopoly-like situation.

The government agency declined to confirm the reports but companies targeted said they were cooperating.

A unit of Swiss-based Nestle, Wyeth Nutrition, responded by slashing its prices in China by as much as 20 percent, while France's Danone said it planned to cut prices as well.

Explore further: China fines LG, Samsung in flat panel price case

Related Stories

China fines LG, Samsung in flat panel price case

January 4, 2013
China fined South Korean and Taiwanese makers of LCD display screens $56 million on Friday for price-fixing, joining the United States and Europe in a crackdown on the industry.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.